Skip to main content

Table 3 Adverse event rates by approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma

From: Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma

  Interferon Bevacizumab with interferon Sunitinib Pazopanib
  Rate (95% CI) Rate (95% CI) Rate (95% CI) Rate (95% CI)
Any grade 3, 4, or 5 0.544 (0.505-0.582) 0.705 (0.670-0.738) 0.734 (0.695-0.769) 0.744 (0.706-0.778)
AE leading to discontinuation of drug 0.185 (0.158-0.217) 0.282 (0.237-0.332) 0.197 (0.173-0.224) 0.244 (0.210-0.281)
AE leading to death 0.013 (0.008-0.022) 0.016 (0.009-0.028) 0.022 (0.014-0.033) 0.023 (0.014-0.040)
Thrombocytopenia 0.135 (0.115-0.157) 0.084 (0.066-0.107) 0.732 (0.703-0.760) 0.410 (0.370-0.451)
Grade ≥ 3 0.009 (0.005-0.017) 0.021 (0.013-0.035) 0.164 (0.141-0.189) 0.036 (0.023-0.055)
Neutropenia 0.320 (0.292-0.350) 0.260 (0.229-0.294) 0.714 (0.684-0.742) 0.366 (0.327-0.407)
Grade ≥ 3 0.069 (0.055-0.087) 0.069 (0.052-0.090) 0.192 (0.168-0.218) 0.045 (0.031-0.066)
Anemia 0.365 (0.336-0.395) 0.132 (0.109-0.159) 0.674 (0.643-0.703) 0.309 (0.272-0.348)
Grade ≥ 3 0.051 (0.039-0.067) 0.033 (0.022-0.049) 0.076 (0.060-0.095) 0.022 (0.012-0.037)
Asthenic conditions or fatigue 0.576 (0.545-0.606) 0.638 (0.602-0.673) 0.593 (0.561-0.624) 0.545 (0.503-0.586)
Grade ≥ 3 0.178 (0.156-0.203) 0.250 (0.220-0.284) 0.146 (0.125-0.171) 0.106 (0.083-0.135)
Diarrhea 0.152 (0.127-0.181) 0.205 (0.165-0.251) 0.589 (0.557-0.621) 0.628 (0.587-0.667)
Grade ≥ 3 0.011 (0.005-0.022) 0.021 (0.010-0.042) 0.082 (0.066-0.102) 0.088 (0.068-0.115)
Nausea 0.467 (0.430-0.504) 0.580 (0.529-0.630) 0.482 (0.450-0.514) 0.446 (0.405-0.487)
Grade ≥ 3 0.030 (0.020-0.045) 0.072 (0.049-0.103) 0.034 (0.024-0.047) 0.022 (0.012-0.037)
Anorexia or appetite loss 0.402 (0.372-0.432) 0.542 (0.505-0.579) 0.358 (0.327-0.389) 0.374 (0.334-0.415)
Grade ≥ 3 0.043 (0.032-0.057) 0.104 (0.084-0.129) 0.029 (0.020-0.042) 0.014 (0.007-0.028)
HTN 0.054 (0.042-0.070) 0.273 (0.242-0.307) 0.364 (0.334-0.396) 0.464 (0.423-0.506)
Grade ≥ 3 0.006 (0.003-0.013) 0.072 (0.055-0.093) 0.137 (0.116-0.160) 0.148 (0.121-0.180)
Proteinuria 0.049 (0.035-0.069) 0.452 (0.416-0.489) 0.137 (0.111-0.168) 0.177 (0.147-0.211)
Grade ≥ 3 0.002 (0.000-0.009) 0.112 (0.090-0.137) 0.040 (0.027-0.060) 0.042 (0.028-0.062)
Pyrexia 0.386 (0.349-0.423) 0.451 (0.399-0.504) 0.128 (0.108-0.151) 0.087 (0.066-0.113)
Grade ≥ 3 0.009 (0.004-0.020) 0.024 (0.012-0.046) 0.011 (0.006-0.020) 0.004 (0.001-0.013)
Headache 0.161 (0.135-0.191) 0.234 (0.192-0.282) 0.186 (0.163-0.213) 0.227 (0.194-0.264)
Grade ≥ 3 0.006 (0.002-0.015) 0.021 (0.010-0.042) 0.011 (0.006-0.020) 0.027 (0.016-0.044)
Thyroid dysfunction 0.010 (0.005-0.020) 0.006 (0.002-0.020) 0.202 (0.177-0.229) 0.121 (0.096-0.151)
Grade ≥ 3 0.006 (0.002-0.014) 0.006 (0.002-0.020) 0.011 (0.006-0.020) 0.000 (0.000-0.007)
Weight loss 0.130 (0.107-0.157) 0.157 (0.124-0.199) 0.085 (0.068-0.104) 0.152 (0.124-0.184)
Grade ≥ 3 0.013 (0.007-0.024) 0.041 (0.025-0.067) 0.005 (0.002-0.013) 0.009 (0.004-0.021)
Dyspnea 0.098 (0.081-0.118) 0.139 (0.115-0.166) 0.143 (0.122-0.167) 0.137 (0.111-0.168)
Grade ≥ 3 0.026 (0.018-0.037) 0.036 (0.024-0.052) 0.023 (0.015-0.035) 0.025 (0.015-0.042)